Missing data methods in HIV clinical trials: Regulatory guidance and alternative approaches

被引:1
|
作者
Kelleher, T
Thiry, A
Wilber, R
Cross, A
机构
[1] Bristol Myers Squibb Co, Dept 703, Biostat & Data Management, Pharmaceut Res Inst, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Co, Infect Dis Clin Res, Pharmaceut Res Inst, Wallingford, CT 06492 USA
来源
DRUG INFORMATION JOURNAL | 2001年 / 35卷 / 04期
关键词
missing data; HIV; clinical trials; regulatory guidance;
D O I
10.1177/009286150103500432
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Efficacy in HIV clinical trials is measured by changes in HIV RNA levels over time as well as the proportion of subjects with HIV RNA levels below an assay's threshold of reliable quantification at a single time point. Missing, data arise naturally due to missed visits and premature discontinuations of treatment. The available data are then analyzed using repeated measures models and univariate comparisons of proportions, assuming missing data occur at random or considering missing values as treatment failures (worst case scenario). These and other methods recently proposed by regulatory authorities are presented along with alternative approaches. Advantages and disadvantages of each method are discussed. Data from a recent comparison of 'standard-of-care' triple combination regimens are used for illustration.
引用
收藏
页码:1363 / 1371
页数:9
相关论文
共 50 条
  • [31] Handling Missing Data in Vaccine Clinical Trials for Immunogenicity and Safety Evaluation
    Li, Xiaoming
    Wang, William W. B.
    Liu, Guanghan F.
    Chan, Ivan S. F.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (02) : 294 - 310
  • [32] A modelling strategy for the analysis of clinical trials with partly missing longitudinal data
    White, IR
    Moodie, E
    Thompson, SG
    Croudace, T
    INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH, 2003, 12 (03) : 139 - 150
  • [33] Methods for Using Data Abstracted from Medical Charts to Impute Longitudinal Missing Data in a Clinical Trial
    Hebert, Paul L.
    Taylor, Leslie T.
    Wang, Jason J.
    Bergman, Margo A.
    VALUE IN HEALTH, 2011, 14 (08) : 1085 - 1091
  • [34] A tutorial for handling suspected missing not at random data in longitudinal clinical trials
    Peugh, James
    Toland, Michael
    Harrison, Heather
    QUANTITATIVE METHODS FOR PSYCHOLOGY, 2023, 19 (04): : 347 - 367
  • [35] Reporting of missing data and methods used to accommodate them in recent analgesic clinical trials: ACTTION systematic review and recommendations
    Gewandter, Jennifer S.
    McDermott, Michael P.
    McKeown, Andrew
    Smith, Shannon M.
    Williams, Mark R.
    Hunsinger, Matthew
    Farrar, John
    Turk, Dennis C.
    Dworkin, Robert H.
    PAIN, 2014, 155 (09) : 1871 - 1877
  • [36] Alternative expectation approaches for expectation-maximization missing data imputations in cox regression
    Saglam, Fatih
    Sanli, Tuba
    Cengiz, Mehmet Ali
    Terzi, Yuksel
    COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2023, 52 (12) : 5966 - 5974
  • [37] Missing Data in Substance Abuse Treatment Research: Current Methods and Modern Approaches
    McPherson, Sterling
    Barbosa-Leiker, Celestina
    Burns, G. Leonard
    Howell, Donelle
    Roll, John
    EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2012, 20 (03) : 243 - 250
  • [38] Endpoints and regulatory issues in HIV vaccine clinical trials - Lessons from a workshop
    Follmann, Dean
    Duerr, Ann
    Tabet, Stephen
    Gilbert, Peter
    Moodie, Zoe
    Fast, Patricia
    Cardinali, Massimo
    Self, Steve
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 44 (01) : 49 - 60
  • [39] Effects of correlation and missing data on sample size estimation in longitudinal clinical trials
    Zhang, Song
    Ahn, Chul
    PHARMACEUTICAL STATISTICS, 2010, 9 (01) : 2 - 9
  • [40] A new way to address missing data in late-stage clinical trials
    Ganju, Jitendra
    Yu, Ron Xiaolong
    CONTEMPORARY CLINICAL TRIALS, 2025, 148